England Launches Innovative Medicines Fund
The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.
You may also be interested in...
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.
Access to Takeda’s lung cancer drug, Exkivity, is being fast-tracked, and BioMarin’s Vimizin, for mucopolysaccharidosis type 4A, is switching to routine use after what the MPS Society called “a long and at times difficult journey.”
Roche’s oral treatment for spinal muscular atrophy and AstraZeneca’s non-small-cell lung cancer drug are among a number of medicines to get the thumbs up from the health technology assessment body, NICE.